张晓翰 蔡云 汪鹏程 范憬超 陈诗彧 杜新

    [摘要]目的应用小剂量利妥昔单抗治疗异基因造血干细胞移植(allo-HSCT)后EBV感染的疗效分析。方法回顾分析深圳市第二人民医院2018年1月至2020年12月38例allo-HSCT后应用小剂量利妥昔单抗治疗EBV感染的疗效并复习相关文献。结果本研究共纳入研究病例38例，其中35例(92.11%)完全缓解(CR)，3例(7.89%)部分缓解(PR)，无患者病情进展为EBV-PTLD。主要不良反应：6例(15.7%)患者出现寒战，5例(13.2%)患者出现发热，2例(5.3%)患者出现胸闷，在给予对症治疗后均缓解，缓解后能够继续完成治疗。结论小剂量利妥昔单抗在早期EBV感染的治疗中取得了较好效果，输注相关的不良反应发生较少，治疗耐受性好。

    [关键词]异基因造血干细胞移植;EBV感染;利妥昔单抗;小剂量

    [中图分类号]R614? [文献标识码]A? [文章编号]2095-0616(2022)02-0024-05

    Analysis on the efficacy of low-dose rituximab in the treatment of EBV infection after hematopoietic stem cell transplantation

    ZHANG Xiaohan? CAI Yun? WANG Pengcheng? FAN Jingchao? CHEN Shiyu? DU Xin

    Department of Hematology，the Second People's Hospital of Shenzhen，Guangdong，Shenzhen 518035，China

    [Abstract]Objective To analyze the efficacy of low-dose rituximab in the treatment of Epstein-Barr virus (EBV)infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods The efficacy of low-dose rituximab for 38 patients with EBV infection after allo-HSCT admitted to the Second People's Hospital of Shenzhen from January 2018 to December 2020 was retrospectively analyzed and the related pieces of literature were reviewed. Results A total of 38 patients were included in this study ......